Pathology and pathogenesis of demyelinating diseases

Current Opinion in Neurology

Volumn 10, Issue 3, 1997, Pages 186-192

  Storch, Maria ^a   Lassmann, Hans ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

MYELIN; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNITY; CELL DAMAGE; CYTOTOXIC T LYMPHOCYTE; DEMYELINATING DISEASE; DISEASE PREDISPOSITION; HUMAN; HYPOTHESIS; IMMUNOPATHOGENESIS; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; REVIEW; T LYMPHOCYTE;

EID: 0030797232     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199706000-00004     Document Type: Review

References (52)

1. Steinman L: Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996, 85:299-302.
2. Cuzner ML, Wekerle H: Symposium: immunopathogenesis of demyelinating diseases. Brain Pathol 1996, 6:229-344. This paper presents a symposium, edited by the authors, containing a series of eight review articles on biochemistry, immunology, pathology and genetics of MS with an additional discussion of animal models and detailed information on mechanisms of demyelination and remyelination.
3. ••].
4. ••].
5. ••] on genetic associations of MS showed multiple genomic hot spots that are associated with MS.
6. Wood NW, Sawcer SJ, Kellar-Wood HF, Holmans P, Clayton D, Robertson N, Compston DA: The T-cell receptor beta locus and susceptibility to multiple sclerosis. Neurology 1995, 45:1859-1863.
7. Wood NW, Sawcer SJ, Kellar-Wood HF, Holmans P, Clayton D, Robertson N, Compston DA: Susceptibility to multiple sclerosis and the immunoglobulin heavy chain variable region. J Neurol 1995, 242:677-682.
8. He B, Navikas V, Lundahl J, Soderstrom M, Hillert J: Tumor necrosis factor alpha-308 alleles in multiple sclerosis and optic neuritis. J Neuroimmunol 1995, 63:143-147.
9. Roth MP, Dolbois L, Borot N, Pontarotti P, Clanet M, Coppin H: Myelin oligodendrocyte glycoprotein (MOG) gene polymorphisms and multiple sclerosis: no evidence of disease association with MOG. J Neuroimmunol 1995, 61:117-122.
10. Chalmers RM, Robertson N, Compston DAS, Harding AE: Sequence of mitochondrial DNA in patients with multiple sclerosis. Ann Neurol 1996, 40:239-243.
11. Losseff NA, Webb SL, O'Riordan JI, Page R, Wang L, Barker GJ, Tofts PS, McDonald WI, Miller DH, Thompson AJ: Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996, 119:701-708.
12. Oro AS, Guarino TJ, Driver R, Steinman L, Umetsu DT: Regulation of disease susceptibility: decreased prevalence of IgE-mediated allergic disease in patients with multiple sclerosis. J Allergy Clin Immunol 1996, 97:1402-1408.
13. Brueck W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar HA, Lassmann H: Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995, 38:788-796.
14. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G: Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci USA 1995, 92:11294-11298. This experimental study in transgenic animals showed that aberrant expression of TNF-α in the CNS leads to demyelination.
15. Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, Compston A: Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996, 119:225-237. An interesting clinical observation is provided suggesting that the release of proinflammatory cytokines during acute anti-T-cell therapy may precipitate clinical signs in MS.
16. Bauer J, Wekerle H, Lassmann H: Apoptosis in brain-specific autoimmune disease. Curr Opin Immunol 1995, 7:839-843 This review summarizes the evidence for T-cell apoptosis as a mechanism for clearance of brain inflammation.
17. Schmied M, Breitschopf H, Gold R, Zischler H, Rothe G, Wekerle H, Lassmann H: Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control Inflammation in the brain. Am J Pathol 1993, 143:446-452.
18. Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJ, Claassen E: CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996, 93:2499-2504. The data presented in this study highlight the importance of costimulatory molecules in the pathogenesis of inflammation in experimental autoimmune encephalomyelitis and MS.
19. Windhagen A, Newcombe J, Dangond F, Strand C, Woodroofe MN, Cuzner ML, Hafler DA: Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995, 182:1985-1986.
20. van Noort JM, van Sechel AC, Bajramovic J, El Ouagmiri M, Polman CH, Lassmann H, Ravid R: A novel candidate autoantigen in multiple sclerosis: αB-crystallin, a small heat shock protein. Nature 1995, 375:798-801. This study shows a prominent autoimmune response in MS patients against alpha-B-crystallin, a stress protein, which is highly expressed in reactive oligodendrocytes in MS lesions.
21. Birch MK, Barbosa S, Blumhardt LD, O'Brien C, Harding SP: Retinal venous sheathing and the blood-retinal barrier in multiple sclerosis. Arch Ophthalmol 1996, 114:34-39.
22. Ronzani M, Lang GE, Wagner P, Lang GK: Severe occlusive retinal periphlebitis with vitreous hemorrhage in multiple sclerosis. Ger J Ophthalmol 1955, 4:328-331.
23. Adelmann M, Wood J, Benzel I, Fiori P, Lassmann H, Matthieu JM, Gardinier MV, Dommair K, Linington C: The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol 1995, 63:17-27.
24. Lorentzen JC, Issazadeh S, Storch M, Mustafa MI, Lassmann H, Linington C, Klareskog L, Olsson T: Protracted, relapsing and demyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and incomplete Freund's adjuvant. J Neuroimmunol 1995, 63:193-205.
25. Lassmann H, Vass K: Are current immunological concepts of multiple sclerosis reflected by the immunopathology of its lesions? Springer Semin Immunopathol 1995, 17:77-87.
26. Kojima K, Berger Th, Lassmann H, Hinze-Seich D, Zhang Y, Germann J, Reske K, Wekerle H, Linington C: Experimental autoimmune panencephalitis and uveoretinitis transfered to the Lewis rat by T-lymphocytes specific for the S100β molecule, a calcium binding protein of astroglia. J Exp Med 1994, 180:817-829.
27. Berger T, Weerth S, Kojima K, Lingington C, Wekerle H, Lassmann H: Experimental autoimmune encephalomyelitis: the antigen specificity of T-lymphocytes determines the topography of lesions in the central and peripheral nervous system. Lab Invest 1997, (In press).
28. Miller SD, McRae BL, Vanderlugt CL, Nikcevich KM, Pope JG, Pope L, Karpus WJ: Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases. Immunol Rev 1995, 144:225-244.
29. Linington C, Bradl M, Lassmann H, Brunner C, Vass K: Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988, 130:443-454.
30. Genain CP, Nguyen MH, Letvin NL, Pearl R, Davis RL, Adelman M, Lees MB, Linington C, Hauser SL: Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest 1995, 96:2966-2974.
31. Prineas JW: The neuropathology of multiple sclerosis. In Handbook of clinical neurology, vol 47. Edited by Koetsier JC. New York: Elsevier Science; 1985:337-395.
32. Selmaj KW, Raine CS: Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988, 23:339-346
33. D'Souza S, Alinauskas K, McCrea E, Goodyer C, Antel JP: Differential susceptibility of human CNS-derived cell populations to TNF-dependent and independent immune-mediated injury. J Neurosci 1995, 15:7293-7300.
34. D'Souza SD, Alinauskas KA, Antel JP: Ciliary neurotrophic factor selectively protects human oligodendrocytes from tumor necrosis factor-mediated injury. J Neurosci Res 1996, 43:289-298.
35. Brosnan CF, Raine CS: Mechanisms of immune injury in multiple sclerosis. Brain Pathol 1996, 6:243-257. This comprehensive review on possible mechanisms of demyelination in MS lesions contains new data on the immunopathology of MS plaques.
36. Dowling P, Shang G, Raval S, Menonna J, Cook S, Husar W: Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 1996, 184:1513-1518.
37. Battistini L, Salvetti M, Ristori G, Falcone M, Raine CS, Brosnan CF: Gamma delta T cell receptor analysis supports a role for HSP 70 selection of lymphocytes in multiple sclerosis lesions. Mol Med 1995, 1:554-562.
38. Raine CS, Wu E, Ivanyi J, Katz D, Brosnan CF: Multiple sclerosis: a protective or a pathogenic role for heat shock protein 60 in the central nervous system? Lab Invest 1996, 75:109-123.
39. Lucchinetti CF, Brueck W, Rodriguez M, Lassmann H: Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996, 6:259-274. This study highlights the heterogenous spectrum of the immunopathology of MS and suggests that different pathogenetic pathways may be responsible for demyelination in different subtypes of MS.
40. Bradl M, Linington C: Animal models of demyelination. Brain Pathol 1996, 6:303-311.
41. Dal-Canto MC, Melvoid RW, Kim BS, Miller SD: Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theller's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Microsc Res Tech 1995, 32:215-229.
42. Allen I, Brankin B: Pathogenesis of multiple sclerosis - the Immune diathesis and the role of viruses. J Neuropathol Exp Neurol 1993, 52:95-102.
43. Carrigan DR, Harrington D, Knox KK: Subacute leukoencephalitis caused by CNS infection with human herpesvirus-6 manifesting as acute multiple sclerosis. Neurology 1996, 47:145-148.
44. Sanders VJ, Waddell AE, Felisan SL, Li X, Conrad AJ: Herpes simplex virus in postmortem multiple sclerosis brain tissue. Arch Neurol 1996, 53:123-124.
45. Ozawa K, Suchanek G, Breitscnopf H, Brück W, Budka H, Jellinger K, Lassmann M: Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994, 117:1311-1322.
46. Prineas JW, Barnard RO, Revesz T, Kwon EE, Sharer L, Cho ES: Multiple sclerosis. Pathology of recurrent lesions. Brain 1993, 116:681-693.
47. Fressinaud C, Vallat JM, Pouplardbarthelaix A: Platelet-derived growth factor partly prevents chemically induced oligodendrocyte death and improves myelin-like membranes repair in vitro. Glia 1996, 16:40-50.
48. Scolding NJ, Compston DA: Growth factors fall to protect rat oligodendrocytes against humoral injury in vivo. Neurosci Lett 1995, 183:75-78.
49. Muir DA, Compston DAS: Growth factor stimulation triggers apoptotic cell death in mature oligodendrocytes. J Neurosci Res 1996, 44:1-11.
50. Yao DL, Liu X, Hudson LD, Webster HD: Insulin-like growth factor-1 given subcutaneously reduces clinical deficits, decreases lesion severity and upregulates synthesis of myelin proteins in experimental autoimmune encephalomyelitis. Life Sci 1996, 58:1301-1306.
51. Miller DJ, Rodriguez M: Spontaneous and induced remyelinationin multiple sclerosis and the Theiler's virus model of central nervous system demyelination. Microsc Res Tech 1995, 32:230-245.
52. Asakura K, Pogulis RJ, Pease LR, Rodriguez M: A monoclonal autoantibody which promotes central nervous system remyelination is highly polyreactive to multiple known and novel antigens. J Neuroimmunol 1996, 65:11-19.